Dumont-UCLA Transplant Center: Clinical Research Program
Overview
Dr. Ronald Busuttil and colleagues established the Dumont-UCLA Transplant Center’s Clinical Research Program in the 1980s. The primary objective over the years has been to study pharmacological agents used in adult and pediatric liver transplant recipients and patients with liver disease. Our Division has participated in numerous phase II-IV single center and multi-center clinical trials and continues to perform a large number of these trials every year.
We have emphasized study of immunosuppressive agents, anti-infective agents (including agents used for hepatitis B and hepatitis C), and agents used to minimize reperfusion injury in adult and pediatric transplant recipients. Others areas of research include liver cancer, pharmacokinetics and pharmacogenomics as well as quality of life studies.
Currently, the Clinical Research Program has several faculty members conducting actively enrolling IRB approved clinical trials. Our research team includes Surgeons, Surgical Fellows, Physicians, Clinical Pharmacists, study nurses and nurse practitioners. Faculty Principal investigators are responsible for overseeing the entire study as well as the IRB and CRC submissions, patient consent, analyzing data and publishing study results. Please contact our Division Office should any additional information be needed regarding our current clinical trials.
Executive Director
Ronald W. Busuttil, MD, PhD
Professor of and Executive Chairman,
William P. Longmire Jr. Chair in Surgery
Director
Curtis D. Holt, PharmD
Clinical Professor
Division Faculty
Douglas Farmer, MD
Sherilyn Gordon Burroughs, MD
Johnny Hong, MD
John Duffy, MD
Gerald Lipshutz, MD
Sue McDiarmid, MD
Sammy, Saab, MD